Yttrium-90 Selective Internal Radiation FAQ, Sirt FAQ, Liver Cancer, Liver Cancer Treatment Singapore, Theranostics

What Is Yttrium-90 Selective Internal Radiation Therapy (SIRT)?

Yttrium-90 Selective Internal Radiation Therapy (SIRT) is known as radioembolisation, and its purpose is to eliminate tumours located in the liver. It involves the injection of small radioactive particles directly into the liver artery. These beads emit short-range radiation, which targets the tumour but minimises damage to the surrounding tissues.

How Effective Is Yttrium-90 Selective Internal Radiation Therapy (SIRT)?

The effect of radioembolisation depends on several factors, including the disease burden underlying liver function and the technique used for dosimetric evaluation. Overall, studies have demonstrated improvements in disease-free progression, reduction in symptoms and improvements in overall survival. 

What Are the Side Effects of Yttrium-90 Selective Internal Radiation Therapy (SIRT)?

In approximately one-third of patients, SIRT administration causes immediate short-term abdominal pain, requiring narcotic analgesia, and is typically self-limiting.

Post-SIRT in the treatment of liver cancer therapy sees lethargy and nausea are common symptoms and can last up to two weeks and may require medication. Most patients develop a mild to a moderate fever that may last for several days following SIRT administration. This fever does not usually require treatment.

The most common and potentially severe complications of SIRT result from either: 

  • Inadvertent administration of SIR-Spheres into the gastrointestinal tract resulting in gastritis/duodenitis
  • Radiation-induced liver disease resulting from a radiation overdose to the normal liver parenchyma

The incidence of gastritis/duodenitis can be reduced by careful attention to the administration procedure to ensure a minimal chance of SIR-Spheres entering the numerous small arteries supplying the gastrointestinal tract.

Radiation-induced liver disease is largely, but not entirely, preventable by using appropriate SIRT doses and making allowances for dose reduction when there is an increased risk of causing radiation damage. Such cases include patients with pre-existing liver damage, poor liver reserve or small volume tumour mass in the liver. 

The reported incidence of gastritis/duodenitis is less than 10%, while the reported rate of radiation-induced liver disease is less than 1%.

The incidence of Radiation Pneumonitis (inflammation of the lungs due to radiation) is expected to be low where appropriate pre-therapy workup and dose reductions are followed. The risk of radiation pneumonitis nevertheless exists and has been reported.

Does Yttrium-90 Selective Internal Radiation Therapy (SIRT) Extend Your Life Expectancy?

While outcomes following radioembolisation depend on various clinical and technical factors, some studies show improvements in progression-free survival, symptoms and overall survival. 

How Many Yttrium-90 Selective Internal Radiation Therapy (SIRT) Treatments Can You Have?

Typically most patients will undergo a single treatment with radioembolisation, but repeated treatments can be done, depending on the clinical needs. 

What Happens After Yttrium-90 Selective Internal Radiation Therapy (SIRT)?

After treatment, the patient will be transferred to a recovery area where they will remain for approximately 1 to 4 hours. During this period, the catheter is removed from the bladder. 

Yttrium-90 Selective Internal Radiation Therapy (SIRT) treatment has several reported side effects. These include: 

  • A fever of more than 38 ° C
  • Abdominal pain
  • Nausea and vomiting

Our specialist will indicate if antipyretic, analgesic and antiemetic medications are necessary.

Click here for more information on Yttrium-90 Selective Internal Radiation Therapy (SIRT) and the treatment of liver cancer through theranostics.

What is Theranostics, Cancer Cells, Theranostics Singapore, Dr Andrew Tan

What Is Theranostics?

Theranostics is a viable method of treating cancer, especially when the cancer cells have spread or are at a more advanced stage and are unable to respond to other treatments.

While there is still a lot of potential to replicate the procedure for other types of cancers, to date, theranostics has shown success mostly in treating liver cancer, metastatic prostate cancer, and neuroendocrine tumours.

Who Invented Theranostics?

The term theranostics was invented in 2002 by John Funkhouser, who was the Chief Executive Officer of PharmaNetics at the time. The term is essentially a combination of the word “therapeutics” and “diagnostics” – a portmanteau describing the PharmaNetics business model for developing diagnostic tests to identify cancer cells and the application of specific therapies.

What Is Theranostics in Nuclear Medicine?

Theranostics in nuclear medicine, or nuclear theranostics, refers to a specific type of cancer treatment.

It targets infection sites by first using diagnostic imaging or a radioactive drug to identify if target receptors are present on cancer cells, followed by a second radioactive drug to deliver therapy to treat the primary tumour and any advanced or metastatic tumours.

Does Nuclear Medicine Have Side Effects?

Only small amounts of radioactive material, known as radiopharmaceuticals or radiotracers, are used in nuclear medicine. These radiopharmaceuticals emit radiation that travels a short and safe distance, which is why very few people experience side effects or allergic reactions from nuclear medicine tests.

Any adverse reactions or side effects are usually mild and need little to no medical treatment. Generally, you should not feel much difference after the radiotracers are administered.

What Is the Theranostic Approach?

The theranostic approach is personalised, using both diagnosis and therapy tools as part of the treatment.

Theranostics in the Treatment of Cancer

Theranostics eliminates the need for multiple procedures to treat cancer, which reduces delays in treatment and improves patient care. In the diagnosis stage, PET scan imaging is used to locate specific targets known as tumour receptors or target receptors present on tumour cells.

As for the therapy stage, once these targets are visible on the scan, a radioactive drug will be injected into the body. This drug is used to treat tumours by selectively targeting the tumour cells and avoiding healthy areas. The radioactive drug that is not utilised or cannot reach the target will be passed out of the body.

What Is Metastatic Prostate Cancer?

Metastatic prostate cancer is an advanced stage of prostate cancer where cancer cells have spread to other parts of the body. It occurs when cells break away from the tumour in the prostate.

During the metastatic stage, these cancer cells usually break away and travel through the lymphatic system in the lymph nodes and the bones or through the bloodstream to other parts of the body.

What Is the Survival Rate for Metastatic Prostate Cancer?

The survival rate of prostate cancer entirely depends on the various stages of cancer. The staging system uses three different aspects of tumour growth – tumour, nodes, and metastasis. Patients whose prostate cancer has spread to other areas like the bones, liver or lymph nodes are in the metastasis stage and may need more advanced treatment.

According to the American Society of Clinical Oncology, about one-third of patients with metastatic prostate cancer will survive for more than five years.

Can Metastatic Prostate Cancer Be Cured?

There are many types of treatment available to slow down the spread of metastatic prostate cancer. Your doctor or oncologist will develop a treatment plan that takes into account your symptoms, stage of cancer, and general health.

What Are the Treatment Options Available For Metastatic Prostate Cancer?

Radiation therapy: External radiation therapy shrinks the tumour in the prostate or kills any new metastasised cancer cells in other areas.

Hormone therapy: This form of therapy lowers the production of male sex hormones, which can help prevent the spread of cancer cells.

Chemotherapy: Chemotherapy prevents cancer cells from multiplying. Patients usually receive chemotherapy once the prostate cancer has stopped responding to hormone therapy.

Immunotherapy: This form of therapy triggers and boosts the immune system to attack cancer cells. Immunotherapy filters immune cells out of the body and stimulates them at a lab to target prostate cancer. These cells are then reinfused back into the patient’s body intravenously (IV).

Bisphosphonate therapy: Patients with prostate cancer that has spread to the bones may undergo bisphosphonate therapy which blocks a bone cell from breaking down other parts of the bone.

How Is Theranostics Used to Treat Metastatic Prostate Cancer?

Radium 223 (Xofigo) is a radioactive drug used in a theranostics procedure to treat castrate-resistant Prostate Cancer, symptomatic Bone Metastases and no known Visceral Metastatic Disease.

The aim of the therapy is to control the bony metastases and to reduce symptoms of bony pain (if present).

Lutetium 177 PSMA is another radioactive drug that is used to treat metastatic castrate resistant prostate cancer, and can target all prostate cancer lesions as long as they express the PSMA ligand on the cell surface.

What Is Hepatocellular Carcinoma (HCC)?

Hepatocellular carcinoma (HCC), also known as primary liver cancer, is a complex heterogeneous cancer. When diagnosing this form of cancer, the choices for treatment will depend heavily on the extent of the cancer and the severity of the underlying chronic liver disease.

What Is the Survival Rate for Hepatocellular Carcinoma?

As Hepatocellular carcinoma is generally diagnosed late in its course, its median survival rate is approximately 6 to 20 months from the time of diagnosis. Globally, it is the 6th most common cancer, and it has become the 2nd most common cause of cancer-related mortality.

Can Hepatocellular Carcinoma Be Cured?

If caught early, it can sometimes be cured with surgery or a transplant. In more advanced cases, it often cannot be cured, but consistent treatment and support can help you live longer, with an improved quality of life.

What Are the Treatment Options Available For Hepatocellular Carcinoma?

There are two types of treatments for Hepatocellular carcinoma; curative and non-curative treatment options.

Curative treatment options include partial liver resection or hepatectomy, local ablation, and liver transplantation, which may provide a high probability of long-term survival.

Non-curative treatment options can be administered when patients are no longer suitable for curative treatment options due to the severity of the disease and condition of the liver or individual’s overall fitness capacity.

Non-curative treatment options that may prolong life are transarterial chemoembolisation (TACE), selective internal radiation therapy (SIRT) with yttrium-90 and systemic therapy. These treatment options are also occasionally used as a neoadjuvant treatment to downstage patients for curative therapy.

How Is Theranostics Used to Treat Hepatocellular Carcinoma?

In theranostics procedures, Yttrium-90 SIRT therapy, a form of Selective Internal Radiation Therapy (SIRT), can be used to treat liver cancer. Yttrium-90 SIRT therapy aims to reduce the size of inoperable tumours that cannot be removed in surgery and/or decrease the number of abnormal cells in the liver. Occasionally, a successful Yttrium-90 SIRT treatment may make it plausible for tumours to be removed surgically.

This form of radiation therapy targets and damages the cancer cells in the liver, reduces the size of the tumours, and prevents the cancer from metastasising further. It is administered via an injection of Yttrium-90 into the main blood vessels in the liver.

What Are Neuroendocrine Tumours (NETs)?

Neuroendocrine tumours (NETs) or neuroendocrine neoplasms (NENs) are rare tumours that develop in cells of the neuroendocrine system.

The World Health Organization (WHO) groups neuroendocrine tumours according to three main categories of tumour grade:

Well-differentiated neuroendocrine tumours, further subdivided into tumours with benign and those with uncertain behaviour
Well-differentiated (low grade) neuroendocrine carcinomas with low-grade malignant behaviour
Poorly differentiated (high grade) neuroendocrine carcinomas, which are the large cell neuroendocrine and small cell carcinomas.

What Is the Survival Rate for Neuroendocrine Tumours?

According to a study conducted on NETs patients from 1973 to 2014, the median survival duration was 41 months. Out of 73,782 NETs patients, the 1-, 3-, 5-, and 10-year overall survival rates were 72.8%, 52.7%, 39.4%, and 18.1%, respectively.

However, general statistics on survival rates must be viewed within the proper context. Your physician should conduct further prognosis depending on your condition.

Can Neuroendocrine Tumours Be Cured?

There are treatments available to prevent the tumours from spreading further. In some cases, neuroendocrine tumours are dormant, small and slow-growing. Studies have shown that slow-growing tumours, when diagnosed early and with proper treatment, can reduce symptoms and limit spreading.

What Are the Treatment Options Available For Neuroendocrine Tumours?

The treatment of neuroendocrine tumours depends on the prognosis and diagnosis of your condition. Treatment options depend on the grade of tumour, which part of the body it originated from, the level of aggressiveness, and how advanced it has spread to distant parts of the body.

How Is Theranostics Used to Treat Neuroendocrine Tumours?

In theranostics procedures to treat neuroendocrine tumours, Lutetium-177 Octreotate therapy (Lu-Octreotate) can be considered a radioactive drug to target radiation on cancer cells without damaging much of the healthy tissue.

Also referred to as Peptide Receptor Radionuclide Therapy (PRRT), Lu-Octreotate therapy combines octreotate, a manufactured form of the naturally produced hormone somatostatin, and lutetium-177, a compound that releases radiation into a tumour.

This theranostic procedure kills abnormal cells, which in turn reduces the size of the NETs tumour from growing further and multiplying. This may mean that the tumour will be relatively dormant for longer periods of time, but it does not mean that NETs can be cured completely.

Liver Cancer, Liver Cancer Causes, Liver Cancer Treatment, Liver Cancer Treatment, Liver Cancer Diagnosis, Theranostics, Theranostics Singapore, Dr Andrew Tan

What Is Hepatocellular Carcinoma?

Hepatocellular Carcinoma (HCC) is the most prevalent type of primary liver cancer. Primary liver cancer is cancer that starts in the liver, whereas secondary liver cancer is cancer that has metastasised or spread from another part of the body to the liver. 

Roughly 90% of all cases of liver cancer appear in this form. It is the 3rd leading cause of all cancer deaths worldwide and is particularly common in developing countries. It affects roughly 2.5 people for every 100,000 people in the population. It is more than two times more common in men than in women and is more prevalent in Eastern and Southern Asia, Middle and Western Africa. The median survival rate is approximately 6 to 20 months from the time of diagnosis.

Hepatocellular Carcinoma tends to have two distinct growth patterns; a single tumour that grows to a significant size before spreading or as many small cancer nodules throughout the liver.

What Causes Hepatocellular Carcinoma?

The exact cause of Hepatocellular Carcinoma is not known, but it is found most commonly in people with underlying liver conditions such as hepatitis B or C, hemochromatosis, biliary stent disorder or fatty liver disease. These conditions end up causing cirrhosis, which in simple terms is ‘liver scarring’. 

As the liver gets damaged by these conditions, scar tissue forms on the liver as it attempts to repair itself. Damage caused by cirrhosis is permanent, so the liver is forced to make new cells to improve overall liver function. 

There is a risk of these new cells mutating and becoming cancer cells. The more cells grown in this way, the higher the chances that a mutation can occur. 

What Are the Symptoms of Hepatocellular Carcinoma?

Hepatocellular Carcinoma will show up the same as many other conditions that indicate poor liver health, such as:

  • Abdominal pain, 
  • Ascites (abnormal buildup of fluid in the abdomen)
  • Bloating
  • Bone pain 
  • Nausea
  • Vomiting
  • A lump or mass under the ribs
  • Loss of appetite
  • Sudden weight loss
  • Shortness of breath 
  • Itching
  • Jaundice

How Is Hepatocellular Carcinoma Diagnosed?

There are three main ways in which Hepatocellular Carcinoma is diagnosed; Lab tests, Imaging Tests, and Biopsies. 

Lab Tests

  1. Alpha Fetoprotein Blood (AFP) Test

AFP is a protein that is found in healthy adults at very low levels. 

High AFP levels in adults indicate the possibility of liver cancer and is the most used tumour marker test for Hepatocellular Carcinoma. The test is typically carried out with several others.

  1. Liver Function Tests (LFTs)

As liver cancer is most often the result of an already debilitated liver, LFTs serve as a good indicator of liver health. They can help understand which parts of the liver have been damaged and to what extent. 

Typically, LFTs test for alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), serum bilirubin, prothrombin time (PT), the international normalised ratio (INR) and albumin.

  1. Des-Gamma-Carboxy Prothrombin (DCP) Test

The DCP test is another cancer marker lab test much like AFP. It is also known as protein induced by vitamin K absence-II (PIV-KAII). 

This test is used in conjunction with AFP tests as it tends to show elevated levels in individuals who have Hepatocellular Carcinoma but who do not show elevated AFP levels.

Imaging Tests

  1. Ultrasound

The ultrasound is usually the very first test used to check for tumours in the liver. It makes use of sound waves to create images on a computer. The tumours typically show up as dark grey (hypoechoic) masses.

  1. Computed Tomography (CT) Scan

Specialised X-ray equipment is used to conduct a CT scan to produce cross-sectional images of the liver. Specific information about the size, shape and location of possible tumours can be evaluated. 

Liver lesions typically show up as masses or areas of abnormal enhancement on multiphasic CT imaging, which in conjunction with blood markers and clinical history, can help the clinician come to a definitive diagnosis. 

  1. Magnetic Resonance Imaging (MRI) Scan

MRI Scans are typically ordered if the CT scan was unable to confirm the diagnosis. MRIs also produce cross-sectional imagery but make use of radio waves instead of X-rays. 

MRI scans can be more accurate and give better imagery in certain circumstances but usually are more costly. Identification requires a skilled assessment of the images.

  1. Positron Emission Tomography (PET) Imaging 

Positron Emission Tomography / Computed Tomography (PET/CT) imaging is a form of hybrid molecular imaging that uses radiotracers to detect and image molecular changes in the body. 

For liver tumours, the more commonly used radiotracers are Fluorodeoxyglucose and Acetate. These tracers are used in metabolic pathways found in hepatocellular carcinomas, and by means of such molecular imaging, we can pinpoint and detect active tumours. 


A biopsy is the most definitive diagnostic test that can be carried out for Hepatocellular Carcinoma. 

It is the process of the removal of a piece of liver tissue for laboratory testing. The removed tissue cells are studied under a microscope, whereby cell mutation can be confirmed as cancerous. 

What Are the Treatment Options Available for Hepatocellular Carcinoma?

Several different treatment options are available for Hepatocellular Carcinoma, and it is not a one-size-fits-all approach. Depending on the individual’s stage, severity, and overall health, different combinations of treatments may be recommended.

Hepatocellular Carcinoma can be somewhat challenging to treat because of how the disease presents itself, developing in a background of cirrhosis, making it difficult to target exclusively. 

1) Radiation

Radiation therapy is the use of high energy beams of protons. The beams are targeted and focused at the cancer cells to kill them while carefully avoiding damage to healthy liver cells. 

Radiation therapy is typically recommended when other treatment options are unsuitable. Radiation therapy also has been shown to play an essential role in downstaging patients who are not eligible for transplant due to the extent of their cancer, possibly improving their condition to make transplant a viable option for them.

Some of the more common side effects of radiation therapy include:

  • Diarrhoea
  • Fatigue
  • Loss of appetite
  • Nausea and vomiting
  • Radiation-Induced Liver Disease
  • Redness to blistering and peeling close to radiated location

2) Chemotherapy

Chemotherapy is the use of drugs that are taken orally or intravenously to kill cancer cells. The drugs can be administered systemically (when cancer has spread) or regionally (more targeted). 

The drugs can also be administered directly into the hepatic artery through a method called Hepatic Artery Infusion so that a higher dose of drugs can be issued. This form of receiving the drugs is done under general anaesthesia and requires an infusion pump.

Compared to radiation, it is considered a non-targeted form of treatment as the drugs affect more than just the cancer site and may result in many unwanted side effects.

The severity and type of side effects depend on the individual and the type and dosage of the drugs prescribed. The most common chemotherapy drugs used for treating Hepatocellular Carcinoma are:

  1. Gemcitabine (Gemzar)
  2. Oxaliplatin (Eloxatin)
  3. Cisplatin (Platinol)
  4. Doxorubicin (Adriamycin)
  5. 5-fluorouracil (Adrucil)
  6. Capecitabine (Xeloda)
  7. Mitoxantrone (Novantrone)

These drugs are often used two or three at a time in combination with each other to achieve the best results. 

Some of the more common side effects of chemotherapy include:

  • Diarrhoea
  • Easy bruising or bleeding 
  • Fatigue
  • Hair loss
  • Increased chance of infections 
  • Loss of appetite
  • Mouth sores
  • Nausea and vomiting

3) Targeted Therapy

Whereas chemotherapy is non-targeted, other drugs can be used for treatment that is targeted. These drugs target the liver specifically instead of being dispersed throughout the entire body and are known as Targeted Therapy. There are two main types of targeted therapies; small molecule medicines and monoclonal antibodies. 

Small molecule medicines enter into cancer cells and destroy them, while monoclonal antibodies work by attacking targets outside the cell to destroy them. 

Small molecule medicines can be identified via their generic names ending with -ib, while monoclonal antibodies have their generic names ending with -mab. 

These drugs work in a variety of ways and have many different mechanisms of action. Targeted therapy works in one of the following ways:

  1. Stopping the creation of new blood vessels that feed the cancer cell
  2. Activating the immune system to attack the cancer cell
  3. Altering proteins within the cancer cell
  4. Shutting down signals that inform the cancer cell to grow or divide
  5. Transporting toxins into the cancer cell

Popular small molecule medicines for early treatment of Hepatocellular Carcinoma are Sorafenib (Nexavar) and Lenvatinib (Lenvima), while Regorafenib (Stivarga) and Cabozantinib (Cabometyx) are used in more advanced stage treatment.

A popular monoclonal antibody for early treatment of Hepatocellular Carcinoma is Bevacizumab (Avastin), while Ramucirumab (Cyramza) is used in more advanced stage treatment.

Some of the more common side effects from targeted therapy include:

  • Bleeding
  • Diarrhoea
  • Headaches
  • High blood pressure
  • Loss of appetite
  • Low white blood cell counts
  • Mouth sores
  • Tiredness 

4) Immunotherapy

As the name suggests, immunotherapy is a treatment that uses the body to activate the immune system to combat cancer. 

Cancer cells tend to mask themselves by turning on proteins that are known as Immune Checkpoint Proteins. When cancer cells use these, they tell the body’s immune system to leave them alone. 

Most immunotherapy drugs work by blocking the binding of the cancer cells to these Immune Checkpoint Proteins and are called Immune Checkpoint Inhibitors. 

These drugs can be classified as either PD-1 and PD-L1 inhibitors or CTLA-4 inhibitors. Commonly used immune checkpoint inhibitors for Hepatocellular Carcinoma are Atezolizumab (Tecentriq) and Ipilimumab (Yervoy).

Some monoclonal antibody targeted therapies are also forms of immunotherapy. One example is Rituximab (Rituxan), which marks cancer cells so that the immune system learns to better identify them and destroy them. 

Some of the more common side effects from immunotherapy include:

  • Constipation or diarrhoea
  • Cough
  • Itching
  • Feeling tired or weak
  • Fever
  • Loss of appetite
  • Muscle or joint pain
  • Nausea
  • Skin rash

5) Surgery

Surgery is usually the best option to cure liver cancer as it is the total removal of the tumour and all cancer cells. The procedure is called a partial hepatectomy, which removes part of the diseased liver. 

The downside here is that only people with a relatively healthy liver with a single tumour and where the cancer has not metastasised into the blood vessels can have this operation. 

The feasibility of the procedure is evaluated via imaging tests. Still, it is also possible that during surgery, the cancer might be found to have grown too large or spread too much, resulting in the surgery being aborted.

Though it may be the best option, it does come with a lot of risks and side effects:

  • Bleeding during and after surgery
  • Blood clots
  • Complications from anaesthesia
  • Infection
  • Pneumonia

6) Liver Transplant

When removal of part of the liver is not an option, and other forms of treatment have proved unsuccessful, a total replacement of the liver via a liver transplant is the best way for a chance at being cured. 

The vast majority of liver transplants come from people who die in accidents or from a donor in the family. The liver has unique regenerative properties, and a portion of it can be donated from a living donor to someone in need of a transplant safely. 

Just like with partial hepatectomy, there are significant risks involved in a liver transplant:

  • Bleeding during and after surgery
  • Blood Clots
  • Complications from anaesthesia
  • Infection
  • Rejection of the new liver

7) Theranostics

Theranostics is the act of using a combination of radiation-based drugs to identify and then kill cancer cells. One drug is used for the identification, and another is used for the treatment – providing a 2 in 1 solution of Therapy plus Diagnostics or Theranostics. 

For treatment of Hepatocellular Carcinoma, in the diagnosis stage, a test study using Technetium 99m Macroaggregated Albumin (MAA) is done to determine the uptake of such particles. These are injected into the liver via the hepatic artery, and following the injection, a scan is done to determine the distribution of particles in the cancer and normal tissue. 

By means of such testing, we are then able to determine an appropriate radiation dose to treat the cancer and yet limit the amount of radiation to normal tissue. 

In the therapy stage, the therapy agent used is Yttrium-90 microspheres. The technique involves delivering Yttrium-90 infused microspheres via the hepatic artery, similar to the initial testing phase. 

The tumour then receives a highly concentrated dose of radiation while the surrounding healthy liver cells receive a much-reduced amount. 

Some of the potential side effects from Yttrium-90 SIRT include:

  • Gastritis/Duodenitis
  • Lethargy
  • Mild to moderate fever
  • Nausea
  • Radiation-Induced Liver Disease

Who Will Benefit from Treatment with Yttrium-90 Selective Internal Radiation Therapy (SIRT)?

The people who benefit most from Yttrium-90 SIRT are those with inoperable tumours that cannot be removed during surgery or where other treatment options have not proved to be beneficial. 

What Are Some Questions I Should Be Asking My Doctor When Considering Treatment Options for Hepatocellular Carcinoma?

  1. Has the cancer spread beyond the Liver?
  2. What stage of cancer do I have?
  3. What treatment options would you recommend?
  4. What are my chances of survival based on what you can see?
  5. How much experience have you had treating this kind of cancer?
  6. Should I consider getting a second opinion?
  7. Should I consider taking part in a clinical trial for new treatments?